Article type : Full length original research paper

Title: Lack of response to quinidine in KCNT1-related neonatal epilepsy

Authors: *Adam L Numis, MD^{1,2}; *Umesh Nair, BS³; Anita N Datta, MD³, Tristan T Sands, MD, PhD⁵; Michael S. Oldham, MD, MPH^{1,5}; Akash Patel, MD²; Melody Li, PhD³; Elena Gazina, PhD³; *Steven Petrou, PhD³; *Maria Roberta Cilio, MD, PhD^{1,2,7}

* These authors contributed equally to the manuscript

Affiliations:

¹ Department of Neurology, University of California San Francisco, San Francisco, California, U.S.A.

² Department of Pediatrics, University of California San Francisco, San Francisco, California, U.S.A.

³ The Florey Institute of Neuroscience & Mental Health, Parkville Victoria, Australia.

⁴ Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

⁵ Department of Neurology, Columbia University, New York, NY, U.S.A.

⁶ Medpace, Cincinnati, Ohio, U.S.A.

⁷ Institute of Human Genetics, University of California San Francisco, San Francisco, California, U.S.A.

Corresponding Author:

Maria Roberta Cilio, MD, PhD

Professor of Neurology and Pediatrics

Department of Neurology and Institute of Human Genetics

UCSF Pediatric Epilepsy Box 0137

Mission Hall Global Health and Clinical Sciences Building

550 16th Street- 4th Floor

San Francisco, CA 94143

University of California, San Francisco

Phone: 415-514-8415

Fax: 415-353-2400

Email: Roberta.Cilio@ucsf.edu

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/epi.14551](https://doi.org/10.1111/epi.14551)

This article is protected by copyright. All rights reserved

Running title: In-vitro and clinical response in EIMFS

Key Words: Epileptic encephalopathy, *KCNT1*, Epilepsy of Infancy with Migrating Focal Seizures, precision medicine, electrophysiology

Number of text pages: 22

Number of words: 3251

Number of References: 35

Number of Figures: 4

Number of Tables: 2

Author Manuscript

Summary:

Objective: To evaluate the clinical efficacy and safety of quinidine in patients with *KCNT1*-related Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) in the infantile period and to compare with the effect of quinidine on mutant channels *in-vitro*.

Methods: We identified four patients with EIMFS with onset in the neonatal period, pathogenic variants in the *KCNT1* gene, and lack of response to AEDs. Patients were prospectively enrolled, treated with quinidine and monitored according to a predefined protocol. Electro-clinical, neuroimaging, and genetic data were reviewed. Two patients had novel variants in the *KCNT1* gene that were modeled in *Xenopus* oocytes with channel properties characterized using electrophysiology recordings.

Results: Three of four patients were treated with quinidine early in their disease course, prior to 6 months of age. There were no significant side effects noted with quinidine therapy. There were also no significant changes in EEG-confirmed seizure burden during therapy and patients had near hourly seizures before, during, and after treatment. Two patients had previously reported gain-of-function mutations which demonstrated sensitivity to high levels of quinidine in the oocyte assay. Two patients with novel variants, showed characteristic gain-of-function and were thus predicted to be pathogenic. Interestingly, these variants were essentially insensitive to high levels of quinidine.

Significance: Patients had no reported benefit to quinidine therapy despite age at treatment initiation. Pharmacogenetic results in oocytes were consistent with clinical treatment failure in two patients, suggesting that single dose pharmacological assessment may be helpful in predicting which patients are exceedingly unlikely to achieve benefit with quinidine. In the two patients who had a lack of therapeutic benefit despite sensitivity to high concentrations of quinidine with *in vitro* oocyte assay, it is likely that the achievable exposure levels in the brain were too low to cause significant *in vivo* channel blockade.

Key Words: Epileptic encephalopathy, *KCNT1*, Epilepsy of Infancy with Migrating Focal Seizures, precision medicine, electrophysiology

Introduction:

Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) is a severe early-onset epileptic encephalopathy with high morbidity. Patients typically have seizure onset in the first six months of age with a clinical course characterized by intractable epilepsy and severe intellectual disability ^{1,2}.

The most common cause are gain-of-function pathogenic variants in the *KCNT1* gene, encoding a sodium-activated potassium channel called SLACK ^{3,4}. Activation of SLACK results in K⁺ efflux, contributing to the modulation of action potential firing behaviour ⁵. Enhanced SLACK current seen in EIMFS patients could trigger epileptogenic firing properties by shortening action potential duration and firing rate. ⁶⁻⁸. Variants in the *KCNT1* gene are also associated with disparate epilepsy syndromes, including autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) as well as other focal epilepsies with variable phenotypes ^{9,10}. However, variants found in patients with EIMFS cause more severe perturbations in channel conductance than in ADNFLE, up to five times greater than normal ¹¹.

Seizures in EIMFS are multifocal, prolonged, arise independently and sequentially from both hemispheres, occur many times each day, and are refractory to nearly all conventional antiepileptic drugs. Some seizure control has been reported with potassium bromide or levetiracetam ¹²⁻¹⁴. The discovery that the class I antiarrhythmic drug quinidine can reverse SLACK channel over-activity *in vitro* led to its rapid clinical application in a patient with EIMFS and a R428Q (c1283 G>A, pArg428Gln) variant with reported *in vivo* efficacy ^{11,15}. Subsequently, reductions in seizure frequency has been observed in few patients, some with functionally milder gain of function mutations in *KCNT1*, but treatment failures in other patients were also reported ¹⁶⁻²⁰. A dissociation with regard to *in vitro* efficacy of quinidine on potassium current and *in vivo* responsiveness has been noted, with a distinct patient with a R428Q variant demonstrating the least effective seizure reduction with quinidine ¹⁷. These findings raise the question about determinants of responsiveness to quinidine, including phenotype, time from symptom onset to the initiation of treatment, or dose.

Here, we report on four patients with *KCNT1*-associated EIMFS, all with onset in the neonatal period, including two patients with novel variants. All patients were treated with quinidine according to a standardized protocol, including two patients treated before two months of age. We report on clinical safety and efficacy for all patients and *in vitro* efficacy for the two previously unreported mutations.

Methods:

Clinical Characteristics:

Patient identification: Patients with the electroclinical phenotype of EIMFS and refractory to multiple anti-

epileptic drugs (AEDs) were identified at the participating centers ¹. As clinically indicated, patients underwent genetic testing with commercially available panels of common epilepsy-associated genes utilizing Sanger sequencing of genomic DNA ²¹. Information was obtained directly from the referring physicians. The original clinical, ictal, and interictal video-electroencephalography (EEG), brain magnetic resonance imaging (MRI), and anti-epileptic drug (AED) treatment of all patients were reviewed by pediatric neurologists and neurophysiologists (ALN, AD, MRC). Developmental delay and cognitive impairment were assessed using developmental milestones, current functioning, and neurological examination. The degree of cognitive impairment was assessed qualitatively with a developmental quotient (DQ) based on acquisition of developmental milestones.

The study was approved by the human research ethics committee of the University of California, San Francisco. Parents assented for off label use of quinidine for the treatment of epilepsy.

Quinidine Treatment: Infants with EIMFS associated with *KCNT1* variants (NM_020822.2) characterized by epileptic encephalopathy and intractable seizures were prospectively approached and trialed on quinidine using a standardized protocol. In brief, prior to quinidine initiation, patients were admitted to the cardiac step-down unit on continuous video-EEG and EKG-telemetry, a standard 12-leads EKG was performed, and patients were given a test dose of quinidine of 2 mg/kg. During admission and prior to quinidine initiation, patients were evaluated with 24-hour video-EEG recording for determination of seizure type, frequency, and duration. Baseline CBC, complete metabolic panels, concomitant AED trough levels, and β -hydroxybutyrate when the ketogenic diet was co-administered were evaluated at baseline. After no side effects were reported to the initial test dose, patients were started on quinidine 15 mg/kg/day divided into 4 doses (maximum 200 mg/dose). Doses were escalated by 15 mg/kg/day at 14-16 day intervals up to a dose of 100 mg/kg/day, as tolerated, with the goal serum quinidine level between 2-5 mg/L.

Prior to each dose increase, patients were admitted for inpatient video-EEG and EKG telemetry to re-evaluate seizure burden. In three of four patients, blood was obtained during each admission for quinidine trough levels, concomitant AED trough levels, and β -hydroxybutyrate when the ketogenic diet was co-administered. A CBC and complete metabolic panel were obtained prior to, and 24-48 hours after each dose escalation. Once on stable dosing of quinidine, patients were re-evaluated with video-EEG and EKG telemetry every three months. All EKGs were reviewed by a board certified pediatric cardiologist.

Electrophysiology:

Oocyte Preparation: *Xenopus* oocytes (Dumont stage V or VI) were surgically removed from *Xenopus laevis* and prepared as described previously ²². Oocytes were kept in ND96 solution and stored at 17°C. Fifty

nanoliters of capped cRNA was injected into each oocyte using the Roboocyte system (Multi Channel Systems, Reutlingen, Germany). A total of 10 ng of cRNA was injected into each oocyte.

KCNT1 Mutagenesis and In Vitro Transcription: A259D (c.776 C>A) and A259V (c.776 C>T) constructs were obtained from Genewiz in a Miniprep form. R1114W (c.3340 C>T) and Del550 (c.1649-1651delAGC, p. Gln550del) mutations were introduced into human *KCNT1* expression construct¹¹ using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. Construct fidelity for all four variants were confirmed by DNA sequencing. cDNAs were transcribed in vitro (mMessage mMachine; Ambion, Austin, TX).

Electrophysiology Recordings: Two-electrode voltage clamp recording was performed using the Roboocyte System (Multi Channel Systems) after 14-48 hours of expression. Electrodes containing 1.5M K-acetate and 0.5M KCl were used to impale oocytes that were held at -90mV and perfused with bath solution containing (in millimolars) 96 NaCl, 2 KCl, 1.8 CaCl₂, 1 MgCl₂, and 5 HEPES, pH 7.5. Recording frequency was 1 kHz, and temperature was maintained between 20 and 22 °C. To record expressed membrane currents, oocytes were held at -90 mV, and test depolarizations lasting for 1000-millisecond were applied at 10 mV increments, from -110 mV to +80 mV, at 5-second intervals. Contemporaneous measurement of WT *KCNT1* currents was performed with the same batch of oocytes injected with variant *KCNT1* mRNA to maintain an internal control of possible variability in expression from different batches of oocytes. Quinidine (Sigma, St Louis, MO) was dissolved in ethanol to a concentration of 300 µM and was perfused continuously to the oocytes for 1 minute, following with 5 minute incubation. Currents were recorded before and after application.

The results obtained was compiled to depict functional differences of each variant (A259D, A259V, R1114W and Q550del) and effect of quinidine on A259D, R1114W and Q550del in comparison to WT (and A259D versus A259V, supplemental Figure 1). Relative current traces, current voltage relationship curves and time to 50% peak curves were employed to determine functional differences between WT and mutants. To determine effect of quinidine, in addition to relative current traces and current voltage relationship curves, the percent of remaining current for mutants (A259D, R1114W and Q550del) and WT was evaluated, after exposure to the compound.

AxoGraph (AxoGraph Scientific, Sydney, Australia) was used to analyse the electrophysiological data while statistical analysis was performed using Graphpad Prism 6 (GraphPad Software, La Jolla, CA). Results are presented as a mean ± standard error of the mean. Statistical significance for current voltage relationship curves and time to 50% peak was determined using two-way ANOVA with Bonferroni *post hoc* analysis while Student *t*-test was used to determine significant differences in percent of remaining current between WT and

A259D mutant. One-way ANOVA with Bonferroni *post hoc* analysis was used to determine significant differences in percent of remaining current between WT, R1114W and Q550del mutants.

Results:

Case Descriptions: All patients had seizure onset in the neonatal period, within two weeks of birth. No patient had pre- or perinatal risk factors for seizures including evidence of hypoxic-ischemic encephalopathy. Seizures were initially focal and rapidly evolved into prolonged multifocal seizures. EEG was initially characterized by multifocal interictal epileptiform discharges, evolving into sub-continuous ictal discharges migrating from one region to another and from one brain hemisphere to another. Seizure duration was approximately 1-3 minutes and patients had multiple seizure per day. Most patient had clusters of multiple seizures per hours. Patients had failed several AEDs at the time of initiation of quinidine (Table 1). Patients began treatment between 1.5 months and 30 months of age, with three of four patients starting treatment within 5 months of age. At the time of treatment, all patients had nearly hourly seizures, often in clusters, lasting 30 seconds to 2 minutes, intractable to multiple AEDs.

Extensive metabolic and neuroradiological testing were unrevealing. Genetic testing showed predicted disease-causing variants in *KCNT1* in all patients. Mutations were previously reported and characterized in two patients [R428Q (c1283 G>A)¹⁶ and M516V (c1546 A>G)²³]. One patient had a novel variant in *KCNT1* at A259D. One patient had one novel variant in *KCNT1*, a *de novo* in-frame Del550 and a paternally-inherited recurrent population variant, R1114W²⁴.

Quinidine Therapy: There were no significant changes in seizure frequency and severity during therapy, with patients having > 1-2 seizures per hour before, during, and after quinidine therapy. Quinidine therapy was stopped before reaching 100 mg/kg/day or a level of 2-5 mg/L in three of four cases due to perceived inefficacy (Figure 1A-B). There were no significant side effects noted during quinidine therapy. There were modest increases in QTc noted with prolonged therapy, though none reaching criteria for prolonged QT (Figure 1C). Quinidine therapy increased trough levels of potassium bromide in one patient and decreased levels another patient, in a dose-independent fashion. Patients on quinidine therapy receiving concomitant phenobarbital, carbamazepine, potassium bromide, or ketogenic diet therapy had no sustained alterations in AED trough levels/ β -hydroxybutyrate (Supplemental Table 1). One patient had 32-37% decreases in levetiracetam levels over the course of quinidine therapy.

Clinical Follow-up: Patients have been followed for 12-24 months after quinidine initiation. At follow-up, one patient died at 15 months of age due to cardiac arrest. This patient had not received quinidine for > 6 months and cause of death was presumed unrelated to quinidine. All other patients continued to have intractable epilepsy. Notably, in all patients potassium bromide in add-on was associated with a decrease in seizure frequency in doses ranging from 50-80 mg/kg/day. All patients were diagnosed with profound developmental delay in keeping with the natural history of EIMFS²⁵. Therefore, there were no significant changes in expected developmental trajectory, positive or negative as a result of quinidine therapy.

Functional characterization of KCNT1 variants: To investigate the functional impact of the unreported *KCNT1* mutants (R1114W-Patient 1, Del550-Patient 1 and A259D-Patient 2) on channel properties, electrophysiological analyses were performed *Xenopus* oocytes. In patient 1, the paternally inherited R1114W allele is a recurrent population variant and was functionally similar to the WT variant and should thus be considered benign. However, the *de novo* Del550 variant found in patient 1 showed a surprising gain-of-function phenotype in both current magnitude and activation kinetics (Figure 2D-F) and is the likely causative mutation. In patient 2 a *de novo* A259D variant was found and functional assessment showed a characteristic gain of function in current magnitude and activation kinetics (Figure 2A-C) as seen in various other EIMFS patients. Previous reports have demonstrated *KCNT1* mutants expressing M516V (Patient 3) or R428Q (Patient 4) result in gain-of-effect with increased K⁺ conductance compared to wild-type channels^{16,23}.

Quinidine sensitivity of KCNT1 variants: To investigate the sensitivity of *KCNT1* variants to quinidine the response to 300 μ M quinidine was measured in the oocyte assay. As reported previously, application of 300 μ M quinidine resulted in a significant reduction in current amplitudes of wild-type channels. In contrast application of 300 μ M quinidine to the A259D and Q550del variant channels revealed a marked insensitivity. Previous reports have demonstrated that application of quinidine to cells expressing mutant M516V (Patient 3) or R428Q (Patient 4) resulted in more pronounced reductions in current amplitudes^{16,23}.

Discussion:

With improvements in cost and availability of genetic testing, there is an increase in the reporting of specific causative mutations in patients with epilepsy²⁶. Here, we report on two novel variants of *KCNT1*, A259D and Q550del with descriptions of both the clinical phenotype and pathologic channel properties. Though our advancements in diagnosis have improved our ability to convey prognosis, the model of precision medicine as it pertains to disease specific treatments in early onset epileptic encephalopathies remains challenging. In *KCNQ2* and *SCN2A* encephalopathy the use of sodium channel blockers can result in seizure freedom without substantial concomitant alterations in long-term neurodevelopmental prognosis, even when therapies are initiated within the first months of life²⁷⁻²⁹. In *KCNT1*-associated EIMFS, quinidine's action can effectively blocks the pathologic constitutive activation of the *KCNT1* channel at the molecular level in some variants¹¹.

Clinical efficacy has been inconsistent¹⁵⁻¹⁷. Similar results have been noted with *KCNT1*-related autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)³⁰

In this case series of four patients with neonatal-onset EIMFS associated with *KCNT1* pathogenic variants, quinidine therapy was safe though did not result in a reduction in clinical seizure frequency or duration, and did not effect neurodevelopment. This is consistent with our *in vitro* results of variants from Patients 1 and 2 that harboured Q550del and A259D that were essentially insensitive to even high doses of quinidine. This is an important finding that has implications for future drug discovery as disease variants could have a range of sensitivity to novel or other repurposed medications. Patients harbouring drug insensitive mutations are unlikely to achieve much therapeutic benefit and such assays should be incorporated in future precision medicine applications in *KCNT1* positive EIMFS.

Patients 3 and 4 harboured mutations that displayed *in vitro* sensitivity to 300 μ M quinidine yet failed to derive any therapeutic benefit. This apparent mismatch in the *in vitro* and *in vivo* response of quinidine therapy may be explained by target-specific tissue concentrations. Quinidine penetrates across the blood brain barrier, with levels varying between 9-46% of unbound plasma levels^{31,32}. After a therapeutic dose of quinidine is administered orally, cerebrospinal fluid concentrations range from 9-15 nM. In modeled human *KCNT1* mutants, 300 μ M is necessary to produce a significant block¹¹. The clinical inefficacy we observed may then be due to inadequate tissue concentrations. We targeted serum quinidine levels to established therapeutic levels of 2-6 μ g/mL. Toxicity can arise at any dose, but certainly at serum levels above 9 μ g/mL. Therefore, further increases in serum levels are unlikely to result in adequate target tissue concentrations without significant cardiovascular side effects. Coupled with our poor appreciation of the extent of *KCNT1* blockade needed for clinical benefit, it is not surprising that quinidine was ineffective. A better understanding of exposure and necessary receptor occupancy may tailor future *in vitro* assays to assess the efficacy of novel therapeutics at lower concentration ranges and predict clinical efficacy in patients with *KCNT1* variants.

Prior case series have described patients with seizure onset in the neonatal period in *KCNT1*-associated EIMFS, though only one case has been diagnosed so early on in the disease course¹⁸. All patients in this series initiated quinidine therapy at an early age, with two patients initiating therapy within the first 2 months of life^{15-18,33}. Despite early targeting of the pathologic channel, no disease modifying effects were noted in the clinical phenotype. In contrast to previous hypotheses, our data does not support 'age at quinidine initiation' as a variable which can modify overall outcome¹⁹. Perhaps then, single gene mutations cause more widespread problems that targeted therapy even when initiated at an early age in development cannot overcome.

While targeting of the *KCNT1* channel with quinidine in EIMFS did not provide benefit, genomic-guided therapy with potassium bromide may ameliorate the epileptic phenotype in this population. Consistent with prior series,

all patients here who received potassium bromide were noted to have reductions in seizure frequency and severity^{12,13}. Though as in *KCNQ2* encephalopathy and *SCN2A* encephalopathy, we do not anticipate bromides to ultimately effect long-term neurodevelopmental prognosis.

The precise mechanism of hyperexcitability driven by mutations in the *KCNT1* gene remains unknown. Does quinidine therapy then truly target the deleterious effects resulting in the epileptic phenotype? The *KCNT1* protein contains a long C-terminal domain allowing for interactions with numerous cytosolic proteins including the protein kinase C (PKC) and fragile-x mental retardation (FRMP) proteins, which independently increase the likelihood of channel opening^{34,35}. We are in need of novel therapeutic strategies that either more specifically target disease genes or impact the network scale changes seen in the early onset epileptic encephalopathies. Early and effective diagnosis, with detailed electroclinical phenotyping and genetic testing still yields the best chances of targeted therapy in a window where we can truly exert changes to neurodevelopment. However, this relationship is undoubtedly complex.

Key Bullet Points:

- EIMFS can present in the neonatal period and is associated with gain-of-function pathogenic variants in the *KCNT1* gene
- Quinidine may reverse the effects of pathogenic *KCNT1* variants *in vitro*
- Quinidine has no impact in seizure burden in patients, even when trialed early in the course of the disease
- Seizure frequency and severity improve with potassium bromide, but the long-term developmental prognosis remains unaltered

Acknowledgements: The authors would like to acknowledge Azita Fatheree for her review of the manuscript.

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosures of Conflicts of Interest:

Dr. Oldham is currently affiliated with Medpace, Cincinnati, OH.

Dr Petrou is a co-founder and equity holder of Praxis Precision Medicines (Cambridge, MA) and RogCon (Miami Beach, FL). He is on the Scientific Advisory Board member and equity holder of Pairnomix (Minneapolis, MN).

Dr. Cilio receives research funding, paid to her Institution, from Insys Therapeutics for company-sponsored trials and received fees and travel support for serving in a scientific advisory board from BioMarin Pharmaceuticals.

The remaining authors have no conflicts of interest to disclose.

References:

1. Coppola G, et al. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. *Epilepsia* 1995;36:1017-1024.
2. McTague A, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. *Brain* 2013;136:1578-1591.
3. Barcia G, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. *Nat Genet* 2012;44:1255-1259.
4. Joiner WJ, et al. Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits. *Nat Neurosci* 1998;1:462-469.
5. Budelli G, et al. Na⁺-activated K⁺ channels express a large delayed outward current in neurons during normal physiology. *Nat Neurosci* 2009;12:745-750.
6. Tang QY, et al. Epilepsy-Related Slack Channel Mutants Lead to Channel Over-Activity by Two Different Mechanisms. *Cell Rep* 2016;14:129-139.
7. Bhattacharjee A, et al. Localization of the Slack potassium channel in the rat central nervous system. *J Comp Neurol* 2002;454:241-254.
8. Kim GE, et al. Human slack potassium channel mutations increase positive cooperativity between individual channels. *Cell Rep* 2014;9:1661-1672.
9. Heron SE, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 2012;44:1188-1190.
10. Moller RS, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. *Epilepsia* 2015;56:e114-120.
11. Milligan CJ, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. *Annals of neurology* 2014;75:581-590.
12. Okuda K, et al. Successful control with bromide of two patients with malignant migrating partial seizures in infancy. *Brain Dev* 2000;22:56-59.
13. Caraballo R, et al. Epilepsy of infancy with migrating focal seizures: six patients treated with bromide. *Seizure* 2014;23:899-902.
14. Cilio MR, et al. Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. *Epilepsy Res* 2009;86:66-71.

15. Bearden D, et al. Targeted treatment of migrating partial seizures of infancy with quinidine. *Ann Neurol* 2014;76:457-461.
16. Mikati MA, et al. Quinidine in the treatment of KCNT1-positive epilepsies. *Ann Neurol* 2015;78:995-999.
17. Chong PF, et al. Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. *Ann Neurol* 2016;79:502-503.
18. Madaan P, et al. A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures. *Brain Dev* 2018;40:229-232.
19. Abdelnour E, et al. Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature. *Seizure* 2018;55:1-3.
20. McTague A, et al. Clinical and molecular characterization of KCNT1-related severe early-onset epilepsy. *Neurology* 2018;90:e55-e66.
21. Mercimek-Mahmutoglu S, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia* 2015;56:707-716.
22. Petrou S, et al. P2X7 purinoceptor expression in *Xenopus* oocytes is not sufficient to produce a pore-forming P2Z-like phenotype. *FEBS Lett* 1997;411:339-345.
23. Rizzo F, et al. Characterization of two de novo KCNT1 mutations in children with malignant migrating partial seizures in infancy. *Mol Cell Neurosci* 2016;72:54-63.
24. Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285-291.
25. Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. *Epilepsia* 2009;50 Suppl 5:49-51.
26. Berg AT, et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. *JAMA Pediatr* 2017.
27. Pisano T, et al. Early and effective treatment of KCNQ2 encephalopathy. *Epilepsia* 2015;56:685-691.
28. Numis AL, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. *Neurology* 2014;82:368-370.
29. Dilella R, et al. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy. *Brain Dev* 2017;39:345-348.
30. Mullen SA, et al. Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. *Neurology* 2018;90:e67-e72.
31. Ochs HR, et al. Entry of quinidine into cerebrospinal fluid. *Am Heart J* 1980;100:341-346.
32. Sindrup SH, et al. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. *Eur J Clin Pharmacol* 1996;49:503-509.
33. Fukuoka M, et al. Quinidine therapy for West syndrome with KCNT1 mutation: A case report. *Brain Dev* 2017;39:80-83.
34. Brown MR, et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. *Nat Neurosci* 2010;13:819-821.

35. Santi CM, et al. Opposite regulation of Slick and Slack K⁺ channels by neuromodulators. *J Neurosci* 2006;26:5059-5068.

Figure Legends:

Figure 1: Association of quinine dose, serum level and QTc interval.

Figure 2: hKCNK1 WT, A259D (A-C) and R1114W/Del550 mutants (D-F) currents recorded in *Xenopus* oocytes.

(A) Representative current traces obtained from *Xenopus laevis* oocytes expressing WT and A259D mutant and (D) WT, R1114W and Del550 mutant. Oocytes were held at -90 mV and stepped from -110 mV to +80 mV for 1000 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Comparison of raw current–voltage relationships of WT (n = 37) and A259D (n = 25), revealed significantly larger currents for the mutant (Two-way ANOVA followed by Bonferroni *post hoc* analysis). (C) Time to 50% peak of currents for WT (n = 28) and A259D (n = 13) exhibited significantly lower time for A259D mutant compared to WT channels (Two-way ANOVA followed by Bonferroni *post hoc* analysis). *p < 0.1, **p<0.01. (E) Comparison of raw current–voltage relationships of WT (n = 37) R1114W (n = 25) and Del550 (n = 27), revealed significantly larger currents for the deletion mutant (Two-way ANOVA followed by Bonferroni *post hoc* analysis). (F) Time to 50% peak of currents for WT (n = 28) and R1114W (n = 11) exhibited no difference between both channels (Two-way ANOVA followed by Bonferroni *post hoc* analysis). Time to 50% peak for Del 550 mutant was not accurate due to quick activation of channel. *p < 0.1.

Figure 3: Application of quinidine onto *Xenopus* oocytes expressing hKCNK1 WT, A259D (A-C) and R1114W/Del 550 mutants (D-F).

(A) Representative current traces obtained from *Xenopus laevis* oocytes expressing WT and A259D mutant and (D) WT, R1114W and Del550 mutant, each with application of vehicle (ND 96) and 300 µM quinidine. Oocytes were held at -90 mV and stepped from -110 mV to +80 mV for 1000 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Raw current–voltage relationships for WT (n = 37) and A259D (n = 15) before and after application of 300 µM quinidine. Current amplitudes reduced significantly in WT and A259D channels (Two-way ANOVA followed by Bonferroni *post hoc* analysis). (C) Average remaining current at +80 mV of WT (n = 37) and A259D (n = 15) hKCNK1 channels after application of 300 µM quinidine showed significant difference between WT and A259D channels (Unpaired t-test). *p < 0.1, **p<0.01. (E) Raw Current–voltage relationships for WT (n = 37), R1114W (n = 16) and Del550 (n = 14) before and after application of 300 µM quinidine. Current amplitudes reduced significantly in WT and R1114 channels with exposure to quinidine

(Two-way ANOVA followed by Bonferroni *post hoc* analysis). (F) Average remaining current at +80 mV of WT (n = 37), R1114W (n = 16) and Del 550 (n = 14) h*KCNT1* channels after application of 300 μ M quinidine revealed significant differences between WT, R1114W and Del 550 (One-way ANOVA followed by Bonferroni *post hoc* analysis). *p < 0.1, **p < 0.01, ****p < 0.0001.

Supplemental Figure 1: Comparison of h*KCNT1* A259D mutant to A259V SNP in *Xenopus* oocytes.

(A) Representative current traces obtained from *Xenopus laevis* oocytes expressing WT, A259D mutant and A259V SNP. Oocytes were held at -90 mV and stepped from -110 mV to +80 mV for 1000 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Comparison of raw current–voltage relationships of WT (n = 37), A259D (n = 25) and A259V (n = 13), revealed significantly larger currents for the A259D mutant compared to the A29V SNP (Two-way ANOVA followed by Bonferroni *post hoc* analysis). Switching from charged (aspartic acid, D) to hydrophobic amino acid (valine, V) changes the functionality of the h*KCNT1* channel. *p < 0.1.

Tables:

Table 1: Genetic, clinical, EEG characterization, and treatment response to quinidine

	Case 1	Case 2	Case 3	Case 4
Genetics				
<i>KCNT1</i> Mutation	1) <i>De Novo</i> c.1649-1651delAGC : p. Gln550del (Del550) 2) Paternal c.3340 C>T: p.Arg1114Trp (R1114W)	<i>De Novo</i> , c.776 C>A : pAla259Asp (A259D)	<i>De Novo</i> c1546 A>G : pMet516Val (M516V)	<i>De Novo</i> c1283 G>A : pArg428Gln (R428Q)
Clinical Characteristics				
GA at birth	38 3/7	39 5/7	41 0/7	Estimated 36, mother did not know of pregnancy until time of delivery
Seizure onset (day of life)	14	1	1	5
Maximum seizure frequency	> 1-2/ hour	> 3-4/hour	> 1-4/hour	~1/hour
Seizure types	Asymmetric focal tonic seizures +/- clonic with	Asymmetric tonic posturing associated with eye/head	Asymmetric tonic posturing associated with eye/head deviation	Type 1: Clonic movements of arms and legs with unilateral

	tachycardia, up to 13 min; myoclonic; epileptic spasms.	deviation with alternating sides	with alternating sides; tongue-thrusting in first month of life.	eye twitching (R or L), +/- lip smacking; Type 2: Eye deviation to right or left, with flushing and increased resp rate; Type 3: electrographic only
Other Clinical	VSD, diffuse hypotonia	Diffuse hypotonia	Diffuse hypotonia	Diffuse hypotonia, right gaze preference
EEG Characteristics				
Interictal background	Lack of organization, diffuse background slowing, abundant multifocal independent SW, PSW, SSW, and random synchronous attenuations.	Lack of organization, diffuse background slowing, abundant multifocal independent SW, random synchronous attenuations.	Lack of organization, diffuse background slowing, abundant multifocal independent SW and PSW	Lack of organization and no well formed sleep architecture. Diffuse background slowing (delta/theta), frequent multifocal spikes SW
Ictal	Tonic: Cessation of interictal SW, background attenuation with multifocal onset and then emergence of rhythmic sharpened alpha with evolution to delta +/- SW.	Tonic: Cessation of interictal SW, background attenuation with superimposed faster frequencies, multifocal in onset, then emergence of rhythmic sharpened alpha.	Tonic: Cessation of interictal SW, background attenuation with superimposed fastest frequencies, multifocal in onset, then emergence of focal rhythmic sharpened theta evolving into frank SW.	With tonic component (Type 2), there is cessation of interictal SW, background attenuation with superimposed faster frequencies, multifocal in onset, followed by emergence of Sharply contoured rhythmic theta with evolution to delta +/- SW. (Type 1 and 3).
MRI Findings	22 mo: Diffuse WM loss (progressive), diffuse T2-WM hyperintensities, MRS mild elevation in choline peak	5 mo: Severe diffuse CC thinning, mild diffuse low WM volume. MRS wnl.	1 mo: Diffuse low WM volume. MRS wnl.	3 mo: Normal

AEDs trialed (* denotes benefit)	CLB, KD, LEV, PB, PHT, TPM, B6, pharmaceutical-grade CBD, KBr (*80 mg/kg/day).	CLB, CZP, KGD, LEV, TPM, PB, PHT, KD, B6, Folinic acid, pharmaceutical-grade CBD, KBr (*80 mg/kg/day)..	CBZ (*), CLB, PB, TPM, B6, KBr (*50 mg/kg/day).	CBZ, CLB, LEV, OXC, TPM, PB (*), B6, KBr (*80 mg/kg/day)..
Quinidine Trial				
Age at initiation	5 months	30 months	2 months	1.5 months
Dose	Up to 100 mg/kg/day (max serum level 1.0) - Ineffective	Up to 80 mg/kg/day (max serum level 2.0) - ineffective	Up to 60 mg/kg/day (max serum level 4.8 mg/L) - ineffective	Up to 50mg/kg/day (max level 1.3) - ineffective

Abbreviations:

- Clinical Characteristics: GA: Gestational age.
- EEG: MF: Multifocal, SW: Spike-wave; SSW: Slow spike-wave; PSW: Polyspike-wave
- MRI: MRS: CC: Corpus callosum; MR Spectroscopy; WM: White Matter; Wnl: within normal limits.
- Medications: AEDs: Anti-epileptic medications; CBZ: carbamazepine; CLB: clobazam; KD: ketogenic diet CZP: clonazepam; LEV: levetiracetam; OXC, oxcarbazepine; PB: phenobarbital; PHT: phenytoin; KBr: potassium bromide; B6: pyridoxine; TPM: topiramate.

epi_14551_f1.tiff

epi_14551_f2.tiff

epi_14551_f3.tiff

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Numis, AL;Nair, U;Datta, AN;Sands, TT;Oldham, MS;Patel, A;Li, M;Gazina, E;Petrrou, S;Cilio, MR

Title:

Lack of response to quinidine in KCNT1-related neonatal epilepsy

Date:

2018-10-01

Citation:

Numis, A. L., Nair, U., Datta, A. N., Sands, T. T., Oldham, M. S., Patel, A., Li, M., Gazina, E., Petrrou, S. & Cilio, M. R. (2018). Lack of response to quinidine in KCNT1-related neonatal epilepsy. *EPILEPSIA*, 59 (10), pp.1889-1898. <https://doi.org/10.1111/epi.14551>.

Persistent Link:

<http://hdl.handle.net/11343/284447>